Treatment of childhood lymphangiomas with interferon-alpha.
OBJECTIVE
Nonsurgical treatment of lymphangiomas has shown limited efficacy and often carries unacceptable toxicities, demonstrating the need for a more effective, less toxic therapy.


METHODS
We describe two patients with lymphangiomatosis treated for 12 to 40 months with recombinant interferon-alpha.


RESULTS
Both patients demonstrated stabilization or marked improvement of disease, based on clinical and radiologic findings, with minimal toxicity.


CONCLUSIONS
The favorable responses to interferon-alpha therapy in these two cases suggest that this is an effective and well-tolerated treatment for lymphangiomas in children.
Reinhardt
M A
MA
Department of Pediatrics, University of Minnesota Hospitals and Clinics, Minneapolis, USA.
Nelson
S C
SC
Sencer
S F
SF
Bostrom
B C
BC
Kurachek
S C
SC
Nesbit
M E
ME
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008202:Lymphangioma / Q000628:therapy*; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000628:therapy; D011994:Recombinant Proteins; D013160:Splenic Neoplasms / Q000628:therapy; D013899:Thoracic Neoplasms / Q000628:therapy
D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins